“it may be just out of an abundance of caution and privacy. certainly, staying a little longer may imply that this is a little bit more of a complex situation.”
.
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
.